Research programme: AAV-based gene therapies - 4D Molecular Therapeutics/Pfizer

Drug Profile

Research programme: AAV-based gene therapies - 4D Molecular Therapeutics/Pfizer

Latest Information Update: 13 Jan 2016

Price : $50

At a glance

  • Originator 4D Molecular Therapeutics
  • Developer 4D Molecular Therapeutics; Pfizer
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders

Most Recent Events

  • 07 Jan 2016 Early research in Cardiovascular disorders in USA (Parenteral)
  • 07 Jan 2016 Pfizer in-licenses AAV vector discovery and optimisation technology from 4D Molecular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top